Slide 1: 1H 2024 Financial Results
1H 2024 Financial Results 25 September 2024
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) has been prepared by Medacta environment in which the Group operates; manufacturing or logistics Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or disruptions; the impact of fluctuations in foreign exchange rates; and the “Group”)
Slide 3: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI CHIEF EXECUTIVE OFFICER
Slide 4: 1H 2024 Highlights
1H 2024 HIGHLIGHTS ● 1H 2024 revenue increased to EUR 288.6 million, or 14.3% at constant currency (c.c.) (13.1% reported) from 1H 2023 ● Strongest growth occurred in EMEA (16.6% c.c.) with continuous progress in APAC (12.6% c.c.) and North America (11.1% c.c.) ● Excellent performance in Knee (+18.6
Slide 5: 1H 2024 Key Financial Figures
1H 2024 KEY FINANCIAL FIGURES* 1 ^ Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency", "EBITDA", "Adjusted EBITDA" or “CORE EBITDA”, "Free Cash Flow", “Adjusted Free
Slide 6: 1H 2024 Capex for Future Growth
1H 2024 CAPEX FOR FUTURE GROWTH R&D Investments Other Intangibles3 EUR 5.6M EUR 0.7M Financial Investments1 EUR 2.4M Other Tangibles2 EUR 11.0M EUR 54.0M Instruments EUR 34.2M 1. Financial Investments include advances on deposits paid for the acquisition of Property, Plant and Equipment. 2. Other Ta
Slide 7: Revenue Bridge by Geographic Area
1H 2024 REVENUE1 BRIDGE BY GEOGRAPHIC AREA 16.6% 11.1% 12.6% 22.3% 14.3% 13.1% 8.5 6.5 0.9 291.5 288.6 LATAM; 5.2; 20.4 (€m) 255.1 -2.9 2% APAC; 54.3; 19% EMEA; 144.2; N.A.; 50% 84.9; 29% 2 1H 23A EMEA NA APAC LATAM 1H 24A c.c. FX 1H 24A EMEA: healthy growth with significant achievements recorded in
Slide 8: Revenue Bridge by Product Line
1H 2024 REVENUE1 BRIDGE BY PRODUCT LINE 7.5% 18.6% 39.6% 10.0% 14.3% 13.1% 7.1 2.2 291.5 288.6 18.3 SPINE; (€m) 255.1 8.7 -2.9 EXTREM.; 24.0; 24.8; 8% 9% HIP; 123.7; 43% KNEE; 116.1; 40% 2 1H 23A HIP KNEE EXTREM. SPINE 1H 24A c.c. FX 1H 24A Hip: good achievements mainly driven by Anterior Minimally
Slide 9: 1H 2019 – 2024: Revenue Trend by Product Line
1H 2019 – 2024: REVENUE TREND BY PRODUCT LINE 123.7 116.4 116.1 101.4 98.5 88.4 (€m) 82.9 77.2 CAGR 1H 2019 – 1H 2024 68.9 63.4 HIP 8.4% 53.7 KNEE 16.3% 47.3 SPINE 18.2% EXTREMITIES 42.4% 22.4 24.0 24.8 16.6 19.8 17.9 Total 13.7% 12.5 12.9 10.9 9.1 4.2 6.1 1H 2019 1H 2020 1H 2021 1H 2022 1H 2023 1H
Slide 10: Corrado Farsetta, Chief Financial Officer
CORRADO FARSETTA CHIEF FINANCIAL OFFICER
Slide 11: 1H 2024 Profit & Loss Statement
1H 2024 P&L1 PROFIT & LOSS STATEMENT (€m) 1H 2024 % 1H 2023 % Revenues 288.6 100.0% 255.1 100.0% Cost of Sales (90.9) -31.5% (79.3) -31.1% GROSS PROFIT 197.7 68.5% 175.9 68.9% CORE R&D expenses (10.0) -3.5% (9.1) -3.6% CORE S&M expenses (105.7) -36.6% (89.5) -35.1% CORE G&A and other expenses (36.5)
Slide 12: Free Cash Flow
1H 2024 FREE CASH FLOW FREE CASH FLOW (€M) 1H 2024 1H 2023 CASH FLOW FROM OPERATING ACTIVITIES 41.8 37.5 CASH FLOW FROM INVESTING ACTIVITIES (54.0) (42.8) FREE CASH FLOW (12.2) (5.3)
Slide 13: Net Financial Debt
NET FINANCIAL DEBT 1 Leverage2 1.0x 1.2x (164.6) (135.2) 31 December 2023 30 June 2024 Notes: 1. For a reconciliation of Alternative Performance Measures please refer to section headed “Alternative Performance Measures” of the 2024 Half-Year Report. The 2024 Half-Year Report is available at https://
Slide 14: 2024 Outlook and Mid-Term Outlook
2024 OUTLOOK Guidance confirmed: revenue growth at constant currency in the range of 13% to 15%, and Adjusted EBITDA margin at constant currency improving around 50 bps from 2023 reported, subject to unforeseen events. MID-TERM OUTLOOK In the mid-term, revenue Compound Annual Growth Rate (CAGR) at c